Monoclonal antibodies against claudin-18 for treatment of cancer
View Patent ↗The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
1. An antibody produced by a clone deposited under the accession no. DSM ACC2737, DSM ACC2739, DSM ACC2742, DSM ACC2745, DSM ACC2748, DSM ACC2808, DSM ACC2809, or DSM ACC2810.
2. A hybridoma deposited under the accession no. DSM ACC2737, DSM ACC2739, DSM ACC2742, DSM ACC2745, DSM ACC2748, DSM ACC2808, DSM ACC2809, or DSM ACC2810.
3. A conjugate comprising an antibody of claim 1 coupled to a therapeutic agent.
4. The conjugate of claim 3 , wherein the therapeutic agent is a toxin, a radioisotope, a drug or a cytotoxic agent.
5. A pharmaceutical composition comprising an antibody of claim 1 and a pharmaceutically acceptable carrier.